![Using Daratumumab to Treat High-Risk Myeloma Patients image](https://healthtree-production.firebaseapp.com/images-resize/?width=920&height=1000&imageUrl=https://storage.googleapis.com/crowdnews-media-library/ce42c97a-2c7f-4b4a-998d-e1df25a6f6e7.png)
Event Description
Is there a benefit associated with adding daratumumab to backbone myeloma treatment regimens among patients with cytogenetically defined high-risk multiple myeloma (HRMM)? Learn from Dr. Luciano Costa on this subject and come with your questions.
Schedule & Agenda
Speakers & Moderators
![The panelist Audrey Burton-Bethke](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2Faud_51e10961-1bcc-4eba-9f38-be0e4b455f81.png?alt=media)
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
![The panelist Luciano Costa, MD, PhD](https://storage.googleapis.com/crowdnews-media-library/28cfc45d-b98d-414c-9673-134d1ac35208.jpg)
Luciano J. Costa, M.D., Ph.D., serves as the Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at UAB. Dr. Costa obtained his M.D. and subsequently Ph.D. from Universidade de Sao Paulo, Brazil. He then trained in hematology and medical oncology at the University of Colorado in Aurora and in blood and marrow transplantation at the Mayo Clinic in Rochester, Minnesota. Prior to joining UAB, Dr. Costa was an Associate Professor of Medicine at the Medical University of South Carolina where he co-chaired the Protocol Review Committee at Hollings Cancer Center. He was recruited to the O’Neal Comprehensive Cancer Center in 2014 as a Senior Clinical Investigator and currently directs the Multiple Myeloma and the Immune Effector Cellular Therapy programs. His primary research focus is the development of new therapies for plasma cell malignancies. Dr. Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma. He is regarded as an international leader in the field with more than 200 peer-reviewed abstracts and publications in high-impact journals such as Blood, Leukemia, the Journal of Clinical Oncology and The New England Journal of Medicine.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)
![Bristol Myers Squibb](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FBristol-Myers_Squibb_logo_(2020).svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)